Jürgen Brockmöller

Jürgen Brockmöller

Auto-generated profile, based on publicly available information

Jürgen Brockmöller

Institute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ESEkkehard Schütz
Ekkehard Schütz
AFAnna Fischer
Anna Fischer
JBJulia Beck
Julia Beck
MHMarkus Harden
Markus Harden
Martina KochMartina Koch
Martina Koch
MOMichael Oellerich
Michael Oellerich
Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker. In liver transplantation (LTx), neither conventional liver function tests (LTFs) nor immunosuppressive drug monitoring are very effective for rejection monitoring. We therefore hypothesized that the quantitative measurement of donor-derived cell-free DNA (cfDNA) would have independent value for the assessment of graft integrity, including damage from acute rejection. Traditional LFTs were performed and plasma GcfDNA was monitored in 115 adults post-LTx at three German transplant centers as part of a prospective, observational, multicenter cohort trial. GcfDNA percentage (graft cfDNA/total cfDNA) was measured using droplet digital PCR (ddPCR), based on a limited number of predefined single nucleotide polymorphisms, enabling same-day turn-around. The same method was used to quantify blood microchimerism. GcfDNA was increased >50% on day 1 post-LTx, presumably from ischemia/reperfusion damage, but rapidly declined in patients without graft injury within 7 to 10 d to a median <10%, where it remained for the 1-y observation period. Of 115 patients, 107 provided samples that met preestablished criteria. In 31 samples taken from 17 patients during biopsy-proven acute rejection episodes, the percentage of GcfDNA was elevated substantially (median 29.6%, 95% CI 23.6%–41.0%) compared with that in 282 samples from 88 patients during stable periods (median 3.3%, 95% CI 2.9%–3.7%; p < 0.001). Only slightly higher values (median 5.9%, 95% CI 4.4%–10.3%) were found in 68 samples from 17 hepatitis C virus (HCV)–positive, rejection-free patients. LFTs had low overall correlations (r = 0.28–0.62) with GcfDNA and showed greater overlap between patient subgroups, especially between acute rejection and HCV+ patients. Multivariable logistic regression modeling demonstrated that GcfDNA provided additional LFT-independent information on graft integrity. Diagnostic sensitivity and specificity were 90.3% (95% CI 74.2%–98.0%) and 92.9% (95% CI 89.3%–95.6%), respectively, for GcfDNA at a threshold value of 10%. The area under the receiver operator characteristic curve was higher for GcfDNA (97.1%, 95% CI 93.4%–100%) than for same-day conventional LFTs (AST: 95.7%; ALT: 95.2%; γ-GT: 94.5%; bilirubin: 82.6%). An evaluation of microchimerism revealed that the maximum donor DNA in circulating white blood cells was only 0.068%. GcfDNA percentage can be influenced by major changes in host cfDNA (e.g., due to leukopenia or leukocytosis). One limitation of our study is that exact time-matched GcfDNA and LFT samples were not available for all patient visits. In this study, determination of GcfDNA in plasma by ddPCR allowed for earlier and more sensitive discrimination of acute rejection in LTx patients as compared with conventional LFTs. Potential blood microchimerism was quantitatively low and had no significant influence on GcfDNA value. Further research, which should ideally include protocol biopsies, will be needed to establish the practical value of GcfDNA measurements in the management of LTx patients.

1 May 2012 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ASAli R. Saadatmand
Ali R. Saadatmand
STSina Tadjerpisheh
Sina Tadjerpisheh
JBJürgen Brockmöller
Jürgen Brockmöller
MTMladen Tzvetkov
Mladen Tzvetkov

3 August 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KRKyra-Elisa Maria Redeker
Kyra-Elisa Maria Redeker
JBJürgen Brockmöller
Jürgen Brockmöller
Organic cations comprise a significant part of medically relevant drugs and endogenous substances. Such substances need organic cation transporters for efficient transfer via cell membranes. However, the membrane transporters of most natural or synthetic organic cations are still unknown. To identify these transporters, genes of 10 known OCTs and 18 orphan solute carriers (SLC) were overexpressed in HEK293 cells and characterized concerning their transport activities with a broad spectrum of low molecular weight substances emphasizing organic cations. Several SLC35 transporters and SLC38A10 significantly enhanced the transport of numerous relatively hydrophobic organic cations. Significant organic cation transport activities have been found in gene families classified as transporters of other substance classes. For instance, SLC35G3 and SLC38A10 significantly accelerated the uptake of several cations, such as clonidine, 3,4-methylenedioxymethamphetamine, and nicotine, which are known as substrates of a thus far genetically unidentified proton/organic cation antiporter. The transporters SLC35G4 and SLC35F5 stood out by their significantly increased choline uptake, and several other SLC transported choline together with a broader spectrum of organic cations. Overall, there are many more polyspecific organic cation transporters than previously estimated. Several transporters had one predominant substrate but accepted some other cationic substrates, and others showed no particular preference for one substrate but transported several organic cations. The role of these transporters in biology and drug therapy remains to be elucidated.

22 April 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MMMarleen J. Meyer
Marleen J. Meyer
PSPascale C.F. Schreier
Pascale C.F. Schreier
MBMert Basaran
Mert Basaran
SVStefaniia Vlasova
Stefaniia Vlasova
TSTina Seitz
Tina Seitz
MTMladen Tzvetkov
Mladen Tzvetkov
Organic cation transporter 1 (OCT1) is a membrane transporter that affects hepatic uptake of cationic and weakly basic drugs. OCT1 transports structurally highly diverse substrates. The mechanisms conferring this polyspecificity are unknown. Here, we analyzed differences in transport kinetics between human and mouse OCT1 orthologs to identify amino acids that contribute to the polyspecificity of OCT1. Following stable transfection of HEK293 cells, we observed more than twofold differences in the transport kinetics of 22 out of 28 tested substrates. We found that the β2-adrenergic drug fenoterol was transported with eightfold higher affinity but at ninefold lower capacity by human OCT1. In contrast, the anticholinergic drug trospium was transported with 11-fold higher affinity but at ninefold lower capacity by mouse Oct1. Using human–mouse chimeric constructs and site-directed mutagenesis, we identified nonconserved amino acids Cys36 and Phe32 as responsible for the species-specific differences in fenoterol and trospium uptake. Substitution of Cys36 (human) to Tyr36 (mouse) caused a reversal of the affinity and capacity of fenoterol but not trospium uptake. Substitution of Phe32 to Leu32 caused reversal of trospium but not fenoterol uptake kinetics. Comparison of the uptake of structurally similar β2-adrenergics and molecular docking analyses indicated the second phenol ring, 3.3 to 4.8 Å from the protonated amino group, as essential for the affinity for fenoterol conferred by Cys36. This is the first study to report single amino acids as determinants of OCT1 polyspecificity. Our findings suggest that structure–function data of OCT1 is not directly transferrable between substrates or species.

26 April 2005 in Das Gesundheitswesen
Verified
Journal Article
Closed access
ARA. Rogausch
A. Rogausch
JBJ. Brockmöller
J. Brockmöller
WHW. Himmel
W. Himmel
Ziel: Die Art der Einbindung pharmakogenetischer Untersuchungen in den medizinischen Alltag wird maßgeblich davon beeinflusst werden, ob und unter welchen Rahmenbedingungen Patienten und Ärzte diese akzeptieren. Ein Literatur-Review sollte die Frage beantworten, welche Implikationen und Konsequenzen Patienten und Ärzte bzw. Wissenschaftler bei der Anwendung pharmakogenetischer Untersuchungen erwarten oder vermuten. Methodik: Umfassende Literaturrecherche in MEDLINE (Stichworte: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) nach empirischen und theoretischen Arbeiten, die psychische, familiäre, soziale und ethische Implikationen pharmakogenetischer Untersuchungen beschreiben, um relevante Themen als Grundlage weiterer empirischer Arbeiten zu extrahieren. Ergebnisse und Schlussfolgerungen: Neben antizipierten Vorteilen könnten folgende Faktoren die Akzeptanz pharmakogenetischer Untersuchungen beeinflussen: Erwartung negativer psychosozialer Konsequenzen sowie Sorge um Diskriminierung oder Nichteinhaltung des Datenschutzes. Zudem dürften die Information über Testergebnisse und die Vermittlung der Implikationen pharmakogenetischer Untersuchungen aufgrund ihrer Komplexität eine Herausforderung in der Arzt-Patienten-Beziehung darstellen. Da sich diese Gesichtspunkte vornehmlich aus theoretisch-konzeptionellen Arbeiten ableiten, sind empirische Untersuchungen zur Einstellung von Patienten und Ärzten sowie zum medizinischen und gesundheitsökonomischen Nutzen pharmakogenetischer Untersuchungen dringend erforderlich. Purpose: Since public acceptance of pharmacogenetic testing will largely influence their implementation in routine medical care, common implications of pharmacogenetic testing from patients’, physicians’ and scientists’ perspective are reviewed. Methods: Broad literature review (MEDLINE; MeSH terms: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) of empirical and theoretical studies describing psychological, family-related, social, and ethical consequences of pharmacogenetic testing to describe relevant aspects for further empirical studies. Results: Apart from anticipated benefit, acceptance of pharmacogenetic testing might be influenced by the following: Expectation of negative psychosocial consequences, fear of discrimination or violation of privacy. Due to its great complexity, understanding of test results and explanation of their impact pose new challenges for physician-patient relations. Since most studies are conceptual, empirical studies exploring attitudes of patients/physicians and determining medical as well as economic value of pharmacogenetic testing are imperative.

1 April 2009 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
Markus SchirmerMarkus Schirmer
Markus Schirmer
AHArne O. Hoffmann
Arne O. Hoffmann
RCRadu Campean
Radu Campean
JJJörg H. Janke
Jörg H. Janke
LZLaura M. Zidek
Laura M. Zidek
JBJürgen Brockmöller
Jürgen Brockmöller
The transforming growth factor-beta (TGFB) pathway has substantial impact on cellular functions, cell proliferation, and apoptosis. We used bioinformatics, gene expression, and cell biological assays to evaluate the functionality of frequent inherited germline polymorphisms in the TGFB receptor 1 (TGFBR1). In an exploratory (n=55) and confirmatory (n=106) study, we analyzed the TGFB1 pathway after incubation with TGFbeta1 ligand and after exposure to X-rays in peripheral blood human mononuclear cells. Expression of TGFB pathway genes was assessed by real-time PCR, and cellular viability was analyzed by flow cytometry. A total of six polymorphisms including the deletion variant (*6A) were identified to tag currently known common genetic variations in TGFBR1 and were analyzed in relation to the phenotypes. In accordance with a negative feedback mechanism, incubations with the ligand TGFbeta1 was followed by up-regulation of the intracellular SMAD7 and down-regulation of the SMAD3 mRNA molecules. The TGFBR1*6A deletion variant attenuated the suppression of SMAD3 in response to TGFbeta1 (P=0.02, in both studies). Moreover, cells harboring *6A were more sensitive toward cytotoxic effects of irradiation (P=0.001 after adjustment for age and sex). Cells were particularly prone toward radiation toxicity when carrying, in addition to *6A, the variant allele of rs11568785, which exhibits a strong genetic selection signature. The *6A deletion and the linked rs11568785 polymorphisms seem to attenuate TGFB signaling. This should be considered not only for clinical-epidemiological studies on cancer susceptibility but may also be relevant for side effects from drugs or radiotherapy.